281. The representative of the Bolivarian Republic of Venezuela noted that the delegation of Canada had described poverty as the main problem for access to medicines. He questioned this statement, noting that poor patients in developing countries sometimes resorted to counterfeit drugs out of despair. The problem therefore was high prices applied by multinational companies which they placed above the public health interests of the poorest nations.